Cam Gallagher - 15 Nov 2021 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Director
Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Cam S. Gallagher
Issuer symbol
ZNTL
Transactions as of
15 Nov 2021
Net transactions value
-$753,619
Form type
4
Filing time
16 Nov 2021, 18:11:08 UTC
Previous filing
05 Nov 2021
Next filing
07 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale $496,192 -6,614 -1.5% $75.02 440,589 15 Nov 2021 Direct F1, F2
transaction ZNTL Common Stock Sale $181,833 -2,400 -0.54% $75.76 438,189 15 Nov 2021 Direct F1, F3
transaction ZNTL Common Stock Sale $75,594 -986 -0.23% $76.67 437,203 15 Nov 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $74.47 to $75.46. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $75.48 to $76.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.49 to $77.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.